204 related articles for article (PubMed ID: 15831699)
1. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.
Boggon TJ; Li Y; Manley PW; Eck MJ
Blood; 2005 Aug; 106(3):996-1002. PubMed ID: 15831699
[TBL] [Abstract][Full Text] [Related]
2. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.
Zhou YJ; Hanson EP; Chen YQ; Magnuson K; Chen M; Swann PG; Wange RL; Changelian PS; O'Shea JJ
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13850-5. PubMed ID: 9391116
[TBL] [Abstract][Full Text] [Related]
3. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
4. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals.
Chen M; Cheng A; Chen YQ; Hymel A; Hanson EP; Kimmel L; Minami Y; Taniguchi T; Changelian PS; O'Shea JJ
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6910-5. PubMed ID: 9192665
[TBL] [Abstract][Full Text] [Related]
5. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
6. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
8. The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors.
Jin L; Pluskey S; Petrella EC; Cantin SM; Gorga JC; Rynkiewicz MJ; Pandey P; Strickler JE; Babine RE; Weaver DT; Seidl KJ
J Biol Chem; 2004 Oct; 279(41):42818-25. PubMed ID: 15292186
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.
Brown K; Long JM; Vial SC; Dedi N; Dunster NJ; Renwick SB; Tanner AJ; Frantz JD; Fleming MA; Cheetham GM
J Biol Chem; 2004 Apr; 279(18):18727-32. PubMed ID: 14766749
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency.
Vihinen M; Villa A; Mella P; Schumacher RF; Savoldi G; O'Shea JJ; Candotti F; Notarangelo LD
Clin Immunol; 2000 Aug; 96(2):108-18. PubMed ID: 10900158
[TBL] [Abstract][Full Text] [Related]
11. Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation.
Nelson BH; McIntosh BC; Rosencrans LL; Greenberg PD
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1878-83. PubMed ID: 9050873
[TBL] [Abstract][Full Text] [Related]
12. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
13. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.
Chen M; Cheng A; Candotti F; Zhou YJ; Hymel A; Fasth A; Notarangelo LD; O'Shea JJ
Mol Cell Biol; 2000 Feb; 20(3):947-56. PubMed ID: 10629052
[TBL] [Abstract][Full Text] [Related]
14. Rapid protein-based assays for the diagnosis of T-B+ severe combined immunodeficiency.
Gilmour KC; Cranston T; Loughlin S; Gwyther J; Lester T; Espanol T; Hernandez M; Savoldi G; Davies EG; Abinun M; Kinnon C; Jones A; Gaspar HB
Br J Haematol; 2001 Mar; 112(3):671-6. PubMed ID: 11260071
[TBL] [Abstract][Full Text] [Related]
15. JAK3 Y841 Autophosphorylation Is Critical for STAT5B Activation, Kinase Domain Stability and Dimer Formation.
Rodriguez G; Martinez GS; Negrete OD; Sun S; Guo W; Xie Y; Li L; Xiao C; Ross JA; Kirken RA
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569303
[TBL] [Abstract][Full Text] [Related]
16. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
17. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
Atwell S; Adams JM; Badger J; Buchanan MD; Feil IK; Froning KJ; Gao X; Hendle J; Keegan K; Leon BC; Müller-Dieckmann HJ; Nienaber VL; Noland BW; Post K; Rajashankar KR; Ramos A; Russell M; Burley SK; Buchanan SG
J Biol Chem; 2004 Dec; 279(53):55827-32. PubMed ID: 15507431
[TBL] [Abstract][Full Text] [Related]
18. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells.
Rane SG; Reddy EP
Oncogene; 1994 Aug; 9(8):2415-23. PubMed ID: 7518579
[TBL] [Abstract][Full Text] [Related]
19. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
20. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.
Zhou YJ; Chen M; Cusack NA; Kimmel LH; Magnuson KS; Boyd JG; Lin W; Roberts JL; Lengi A; Buckley RH; Geahlen RL; Candotti F; Gadina M; Changelian PS; O'Shea JJ
Mol Cell; 2001 Nov; 8(5):959-69. PubMed ID: 11741532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
